SELLAS LIFE SCIENCES GROUP INC (SLS)
Health Care · biotechnology · NASDAQ
SELLAS Life Sciences is a clinical-stage biotech developing novel immunotherapies to address hematologic and solid tumor cancers.
What SELLAS LIFE SCIENCES GROUP INC does
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies. The company is primarily engaged in the development of product candidates designed to treat various hematologic malignancies and solid tumors.
Themes: oncology, immunotherapy, clinical-stage biotech
Fundamentals
- Price$11.26 as of 2026-10-08 close
- Market cap$2.3B as of 2026-08-10 (share count; price 2026-10-08)
- 1-year return+483.4% 2025-10-08 close $1.93 → 2026-10-08 close $11.26
- P/En/a negative earnings
- ROE-37.9% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta0.86 as of 2026-09-02
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How SLS compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which SLS reported a dividend payment is FY2018, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2018 ratio would not describe SLS today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2018) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How SELLAS LIFE SCIENCES GROUP INC looks technically
SELLAS LIFE SCIENCES GROUP INC (SLS) is trading 41.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 391 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-08-11, breaking below its recent trading range. It is 29.1% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 41.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +41.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.37 | $12.37 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.96 | $7.96 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 12.53. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 391 trading days ago — a "golden cross", a bullish long-term signal | 391 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend) | 14.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 43.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($10.71 to $12.53) — its "stochastic" reading is 30 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 30.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 27 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $15.88 | $15.88 |
|---|---|---|
| From the 52-week high | it is 29.1% below its 52-week high (its highest price of the past year) | -29.1% |
| Above the 52-week low | it is 710.1% above its 52-week low (its lowest price of the past year) | +710.1% |
| Below the 52-week high | it is 29.1% below its highest point of the past year | 29.1% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-08-11, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $718500.00 (set on 2008-03-12) | $718500.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.39 to $15.46), and it has given back roughly a quarter of its rise from last year’s low — 30% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.31 to $6.76. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 29.9% |
| From the all-time high | it is 100.0% below its all-time high | -100.0% |
| Nearest price level | it is trading 4.0% above a support level at $10.81 — a price it turned at twice since 2026-08-11, most recently on 2026-09-14. Since 2024-10-08 it has 5 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.0% |
| All-time low | its lowest closing price on record is $0.5 (set on 2024-01-08) | $0.5 |
| Above the all-time low | it is 2152.0% above its all-time low | +2,152% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8126 between its high and its low — about 7.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8126 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.06 and $12.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.06 – $11.59 – $12.12 |
| Typical daily range (% of price) | its price moves about 7.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.2% |
| Stretch from the 200-day average | it is trading 4.1 daily ranges above its 200-day average price (41.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.66× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.2% |
|---|---|---|
| Open gap | it gapped 2.1% below the previous close 20 sessions ago and has not traded back through the level it left behind at 13.95 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.1% |
| Gap filled | a 3.0% gap down opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 4 sessions in a row, a -4.09% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 4 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 20.4 percentage points (the stock lost 19.3% while the market gained 1.0%) | -20.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 22.0 percentage points (the stock lost 18.2% while the market gained 3.8%) | -22.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 131.1 percentage points (the stock gained 148.6% while the market gained 17.5%) | +131.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 468.4 percentage points (the stock gained 483.4% while the market gained 15.0%) | +468.4% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 12.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -5.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 35% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $8.36 — a volume-weighted average of daily closes over 193 sessions, not a true tick-by-tick VWAP. | +34.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% below the average price paid since it last reported on 2026-07-27 (its 8-K), so the typical buyer over that stretch is under water. That average is $12.43 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -9.4% |
Double top, bearish — forming · entry $10.01 · 71 sessions in
Price levels it has turned at before
SLS last closed at $11.26 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $10.81 | Support | 4.0% below the last close | turned there twice · 2026-08-11 to 2026-09-14 |
| $12.59 | Resistance | 11.8% above the last close | turned there twice · 2026-09-01 to 2026-09-30 |
| $15.78 | Resistance | 40.1% above the last close | turned there twice · 2026-06-30 to 2026-08-21 |
| $5.18 | Support | 54.0% below the last close | turned there twice · 2026-01-05 to 2026-04-09 |
| $1.84 | Support | 83.6% below the last close | turned there twice · 2025-02-03 to 2025-05-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $12.53.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 14 trading days, since 2026-09-21.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$32.50 range $30.00 – $35.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SLS
- Consensus EPS estimate-$0.05 next reporting period, as of 2026-10-05
- Estimate change, 30 days-$0.005 from -$0.045, on 2026-08-31, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant risks associated with the success of preclinical and clinical development programs.","Dependence on the ability to raise additional capital to fund ongoing operations.","High uncertainty regarding the regulatory approval and market acceptance of product candidates."]
What changed in the latest 10-Q
AI-assisted comparison of SLS's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K filed on March 19, 2026 (newer filing, filed 2026-05-12)
- Updated enrollment figure: 'We planned to enroll approximately 125 to 140 patients' (newer filing, filed 2026-05-12)
- Statement: 'Our contract research organization informed us that the pooled number of events was 78 as of May 11, 2026' (newer filing, filed 2026-05-12)
- Clarification: 'We remain blinded to all efficacy and survival data outcomes and, as no outcomes analyses were performed and no statistical penalty has been incurred, this one-time update on the aggregate number of events does not impact future statistical analyses' (newer filing, filed 2026-05-12)
- Statement: 'We will announce the 80th event when it occurs' (newer filing, filed 2026-05-12)
- Updated date reference: 'As of March 31, 2026, we have received an aggregate of $10.5 million' (newer filing, filed 2026-05-12)
- SLS009 subsection header changed to include 'or Tambiciclib' (newer filing, filed 2026-05-12)
- Updated RP2D information: '60 mg once weekly or 30 mg twice weekly for AML' (newer filing, filed 2026-05-12)
- Removed:
- Specific enrollment number: '126 patients' removed; replaced with range 'approximately 125 to 140 patients' (older filing, filed 2025-11-12)
- Statement: 'Study sites in the U.S. and Europe account for approximately 75% of patients enrolled, with the U.S.-based sites representing the highest enrolling country' (older filing, filed 2025-11-12)
- Statement: 'In August 2025, we announced the completion of a periodic review by the IDMC and positive recommendation to continue the REGAL study without modification' (older filing, filed 2025-11-12)
- Statement: 'We anticipate that 80 events will be reached this year' (older filing, filed 2025-11-12)
- Date reference: 'As of March 15, 2025' changed to 'As of March 31, 2026' (older filing, filed 2025-11-12)
- Form 10-K reference date: March 20, 2025 (older filing, filed 2025-11-12)
- Reference to 2024 Annual Report (older filing, filed 2025-11-12)
- RP2D wording: '60 mg once weekly for AML' changed to '60 mg once weekly or 30 mg twice weekly for AML' (older filing, filed 2025-11-12)
- Abbreviation: 'OS' changed to 'overall survival, or OS' in CDK9 description (older filing, filed 2025-11-12)
- Reworded:
- SLS009 subsection header: 'SLS009: Highly Selective Next Generation CDK9 Inhibitor' changed to 'SLS009, or Tambiciclib: Highly Selective Next Generation CDK9 Inhibitor' (newer filing, filed 2026-05-12)
- CDK9 impact description: 'correlate negatively with OS' changed to 'correlate negatively with overall survival' (newer filing, filed 2026-05-12)
- Phase 2a trial dose wording: 'or 30 mg twice a week' changed to 'or 30 mg twice weekly' (newer filing, filed 2026-05-12)
- Notes:
- Older filing text is truncated at end of SLS009 section, preventing full comparison of remaining content
- Reference dates differ significantly: newer filing is as of March 31, 2026; older filing is as of September 30, 2025
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
Most recent open-market transaction: 2025-11-19. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SLS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SLS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 41,612,957
- Reported value $614,207,248
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SLS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SLS had 59,068,630 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
SLS had 29.2% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.6 days to cover at the same settlement.
- Reported short interest (shares) 59,068,630
- Short interest (% of shares outstanding) 29.2%
- Prior settlement (shares) 57,926,912
- Reported change 1.97%
- Days to cover (reported) 8.6
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (GILD)
- Bristol Myers Squibb (BMY)
- Merck (MRK)
- Novartis (NVS)
- AstraZeneca (AZN)
- Pfizer (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SLS vs…
SELLAS LIFE SCIENCES GROUP INC is found in…
SLS ranks in…
Frequently asked questions
What does SELLAS LIFE SCIENCES GROUP INC (SLS) do?
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies. The company is primarily engaged in the development of product candidates designed to treat various hematologic malignancies and solid tumors.
What sector is SELLAS LIFE SCIENCES GROUP INC (SLS) in?
SELLAS LIFE SCIENCES GROUP INC (SLS) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are SELLAS LIFE SCIENCES GROUP INC's (SLS) competitors?
Notable peers of SELLAS LIFE SCIENCES GROUP INC (SLS) include Gilead Sciences, Bristol Myers Squibb, Merck, Novartis and AstraZeneca. This peer set is informational only — not financial advice.
Is SELLAS LIFE SCIENCES GROUP INC (SLS) overbought or oversold right now?
SELLAS LIFE SCIENCES GROUP INC (SLS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SLS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.